Evidence map›Paper›PMID 29602908›Full record

ReviewCancer prevention research (Philadelphia, Pa.)2018

A Review of Promising Natural Chemopreventive Agents for Head and Neck Cancer.

Kyle Crooker, Rana Aliani, Megha Ananth, Levi Arnold, Shrikant Anant, Sufi Mary Thomas

Open access · greenAbstract readReview
In one paragraph

Review in Cancer prevention research (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kyle Crooker *Department of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas.
Rana Aliani *Department of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas.
Megha Ananth *Department of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas.
Levi ArnoldDepartment of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas.
Shrikant AnantDepartment of Surgery, University of Kansas Medical Center, Kansas City, Kansas.
Sufi Mary ThomasDepartment of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas. sthomas7@kumc.edu.
University of Kansas Medical Center · US

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
Using PCORnet to Expand the DS-CONNECT Cohort Through Healthcare System Recruitment, Incorporating Electronic Health Records, and Assessing Self-DeterminationU54HD090216 · NICHD · UNIVERSITY OF KANSAS LAWRENCE · PI COLOMBO, JOHN A. · 2016 to 2020
$6.2M
Bitter Melon Component and Colon Cancer PreventionR01CA190291 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ANANT, SHRIKANT, UMAR, SHAHID · 2014 to 2018
$2.7M
Role of autophagy in the tumor microenvironmentR01CA227838 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI THOMAS, SUFI MARY · 2019 to 2023
$1.9M
NCI NIH HHS P30 CA168524NCI NIH HHS R01 CA190291NCI NIH HHS R01 CA227838NICHD NIH HHS U54 HD090216
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) accounts for 300,000 deaths per year worldwide, and overall survival rates have shown little improvement over the past three decades. Current treatment methods including surgery, chemotherapy, and radiotherapy leave patients with secondary morbidities. Thus, treatment of HNSCC may benefit from exploration of natural compounds as chemopreventive agents. With excellent safety profiles, reduced toxicities, antioxidant properties, and general acceptance for use as dietary supplements, natural compounds are viewed as a desirable area of investigation for chemoprevention. Though most of the field is early in development, numerous studies display the potential utility of natural compounds against HNSCC. These compounds face additional challenges such as low bioavailability for systemic delivery, potential toxicities when consumed in pharmacologic doses, and acquired resistance. However, novel delivery vehicles and synthetic analogues have shown to overcome some of these challenges. This review covers 11 promising natural compounds in the chemoprevention of HNSCC including vitamin A, curcumin, isothiocyanate, green tea, luteolin, resveratrol, genistein, lycopene, bitter melon, withaferin A, and guggulsterone. The review discusses the therapeutic potential and associated challenges of these agents in the chemopreventive efforts against HNSCC.

Indexed as

Antineoplastic Agents, PhytogenicBiological AvailabilityBiological ProductsDrug Delivery SystemsDrug Resistance, NeoplasmHead and Neck NeoplasmsHumansNanoparticlesSquamous Cell Carcinoma of Head and NeckTreatment OutcomeAntineoplastic Agents, PhytogenicBiological Products

Identifiers

PMID29602908
PMCPMC6072563
OpenAlexW2794600699

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.